Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.54 |
| ▸ | CHRNA3 known ✓ | P32297 | 1/20 | 0.50 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.48 |
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.42 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CHKA | P35790 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.50 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1408979 | 1.00 | CA2 (0.54) | CA2CA12CA1CA9CHKA | |
| Hydrochloric Acid SCHEMBL18116041 | 1.00 | CA2 (0.54) | CA2CA12CA1CA9CHKA | |
| SCHEMBL6961568 | 0.97 | — | — | |
| SCHEMBL15319 | 0.97 | — | — | |
| SCHEMBL17100538 | 0.97 | CA2 (0.56) | CA2CA12CA1CA9CHKA | |
| Water SCHEMBL11193463 | 0.94 | CA2 (0.54) | CA2CA12CA1CA9CHKA | |
| Ammonia Solution, Strong SCHEMBL4674734 | 0.94 | CA2 (0.54) | CA2CA12CA1CA9CHKA | |
| Water SCHEMBL10607939 | 0.94 | CA2 (0.54) | CA2CA12CA1CA9CHKA | |
| SCHEMBL5031106 | 0.94 | CA2 (0.54) | CA2CA12CA1CA9CHKA | |
| SCHEMBL31040426 | 0.94 | CA2 (0.54) | CA2CA12CA1CA9CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637702-B2 | Process for preparing substituted imidazo[1,5-α]pyrazines | HOFFMANN-LA ROCHE INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20230175026-A1 | Process for the Preparation of a Chiral Piperazine-2-carboxylic Acid | HOFFMANN-LA ROCHE INC. (US) | 2023-06-08 | — | — | US | disclosed |
| CN-115461333-A | Process for the preparation of chiral piperazine-2-carboxylic acid | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-115093382-A | Crystalline forms of a MAGL inhibitor | H.隆德贝克有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-110291083-B | Crystalline forms of a MAGL inhibitor | H.隆德贝克有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-107660202-B | Water-soluble prodrugs | 大日本住友制药肿瘤公司 | 2021-12-24 | — | — | CN | disclosed |
| CN-106110332-B | Protein-polymer-drug conjugate | 梅尔莎纳医疗公司 | 2018-11-30 | — | — | CN | disclosed |
| CN-107868071-A | 7,8 5,7-Dihydroxyflavones and chromocor derivative, composition and its correlation technique of 7,8 substitutions | 爱默蕾大学 | 2018-04-03 | — | — | CN | disclosed |
| CN-104812744-B | 7, 8-dihydroxyflavone and 7, 8-substituted flavone derivatives, compositions, and methods related thereto | 爱默蕾大学 | 2017-12-01 | — | — | CN | disclosed |
| CN-106110332-A | Protein polymer drug conjugate | 梅尔莎纳医疗公司 | 2016-11-16 | — | — | CN | disclosed |
| US-20120178738-A1 | DIBENZO [B,F] [1,4]OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| EP-2137180-B1 | DIBENZO [B,F][1,4] OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-8093237-B2 | 11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazapine compounds; psychological disorders, sleep disorders; antipsychotic agents that modulate monoaminergic neurotransmitter receptor subtypes; side effect reduction | ARYX THERAPEUTICS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| CN-101641350-A | Dibenzo [ b ] | ARYX THERAPEUTICS INC US | 2010-02-03 | — | — | CN | disclosed |
| EP-2137180-A1 | DIBENZO [B,F][1,4] OXAZAPINE COMPOUNDS | Aryx Therapeutics, Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | PROTOCELL THERAPEUTICS INC. | 2008-10-16 | — | — | US | disclosed |
| WO-2008112900-A1 | DIBENZO[B,F][1,4]OXAZAPINE COMPOUNDS | ARYX THERAPEUTICS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| EP-1592389-A2 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004071390-A2 | PIPERAZINE-2-CARBOXAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2004-08-26 | — | — | WO | disclosed |
| US-5856485-A | RESOLUTION OF AN ENANTIOMORPH MIXTURE | LONZA AG (CH) | 1999-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230175026-A1 | Process for the Preparation of a Chiral Piperazine-2-carboxylic Acid | HAVCR2, HCCS, DHPS | CA2 834/4885CHRNA3 4398/4885SIGMAR1 2425/4885 |
| US-20120178738-A1 | DIBENZO [B,F] [1,4]OXAZAPINE COMPOUNDS | DBH, DRD4, PSEN1 | CA2 4707/4885CHRNA3 511/4885SIGMAR1 1180/4885 |
| US-20080255088-A1 | DIBENZO[b,f][1,4]OXAZAPINE COMPOUNDS | DBH, DRD4, PSEN1 | CA2 4707/4885CHRNA3 511/4885SIGMAR1 1180/4885 |
| US-12637702-B2 | Process for preparing substituted imidazo[1,5-α]pyrazines | BCKDK, P4HB, DOHH | CA2 1502/4885CHRNA3 4445/4885SIGMAR1 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.